

Product Data Sheet

Bemfivastatin

Cat. No.: HY-106281

CAS No.: 805241-79-6

Molecular Formula: C₃₄H₃₇FN₂O₆

Molecular Weight: 588.67

Target: HMG-CoA Reductase (HMGCR)

Pathway: Metabolic Enzyme/Protease

Storage: 4°C, sealed storage, away from moisture and light

* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (169.87 mM; Need ultrasonic)

| | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|-----------|------------|
| Preparing Stock Solutions | 1 mM | 1.6987 mL | 8.4937 mL | 16.9874 mL |
| Stock Solutions | 5 mM | 0.3397 mL | 1.6987 mL | 3.3975 mL |
| | 10 mM | 0.1699 mL | 0.8494 mL | 1.6987 mL |

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.25 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are \geq 320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins [1][2].

| 1 Miorabioli A at al Durin | in dovolonment for the many | ont of ductionidae asia [1] Future 5 | Procesibor 2012 12/2), 12 15 | | |
|--|-----------------------------|--------------------------------------|---|--|--|
| 2]. Wierzbicki A, et al. Drugs in development for the management of dyslipidaemia[J]. Future Prescriber, 2012, 13(2): 12-15. | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | Caution: Product has not b | oeen fully validated for med | ical applications. For research use only. | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |
| | Tel: 609-228-6898 | Fax: 609-228-5909 | E-mail: tech@MedChemExpress.com | | |